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A recent article on xenotransplantation (R. Finn, The Scientist, Aug. 19, 1996, 
page 1) and two published responses to my commentary (M. Jasienski, The 
Scientist, March 4, 1996, page 10), which was critical of a single-subject baboon 
Bone-marrow transplant trial, prompt me to explicate some methodological 
issues further. 
What insights can a single-subject study provide? While, as pointed out by 
J.E. Janosky (The Scientist, May 27, 1996, page 12), there could be some room for 
N = 1 studies (see e. g. H. Motulsky, Intuitive Biostatistics, New York, Oxford University 
Press, 1995), a letter by J.G. Llaurado (The Scientist, July 8, 1996, page 
12) unintentionally strengthens my skepticism in this matter. Llaurado writes 
that the currents that Alessandro Volta used on himself to study electricity are 
"today believed sufficient to cause lethal arrhythmias on a less corpulent man 
than Volta." Is it then not quite fortunate for the development of science that 
Volta was overweight (that is, not representative of the whole population)? How 
many Voltas were there who were scrawny and, consequently, electrocuted? I 
suspect that many similar single-subject experiments gain from selective 
memory. 
There is a deeper point, though. Any empirical science moves from 
general demonstrations to refinements. Single-subject demonstrations of the 
applicability of laws of nature rely on the subject's being roughly representative 
of its kind. You've seen one, you've seen them all apples falling to the ground. 
This is because the property we focus on (mass, rather than, say, color) has 
indeed the greatest bearing on the phenomenon we are trying to explain (apple's 
falling down). How often can we be sure, however, which properties as 
expressed in a John Doe are robustly representative of the responses of all 
mankind? Granted, it has certainly worked in the past, as Llaurado correctly 
points out, but the lucky single subjects were representative of the human 
species only because the questions were about some of the most fundamental 
phenomena. Our knowledge becomes more and more subtle, however. Rough 
ideas, approximate explanations, and nonmechanistic predictions are no longer 
sufficient, especially in medicine. 
While I am full of admiration for Jeff Getty's perseverance and fortitude in 
his involvement in the baboon bone-marrow transplant trial, I would wish the 
results of his efforts were not rendered uninterpretable by the weakness of the 
experimental design. I hope that the Food and Drug Administration and the 
medical establishment are equally determined to follow Getty's leadership with 
the state-of-the-art statistical methodology. A high-tech approach is a necessary, 
but not a sufficient, component of a successful study. Statistically sound design 
will always be a condition sine qua non. Alas, N = 1 is not it. 
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